Cortexyme, Inc., a company developing novel disease modifying therapeutics for Alzheimer’s and other degenerative disorders today announced it will participate in the 4th Annual Silicon Valley Bank & DLA Piper Healthcare Connect 2016 conference, in Sonoma, California June 9-10, 2016.
Casey Lynch, co-founder and CEO of Cortexyme, will provide an update on the company’s recent financing and product development progress at 11 a.m. on Friday June 10.
Healthcare Connect is a gathering of strategic investors and select CEO’s in Napa Valley California.
Cortexyme is a private company based in South San Francisco, California developing therapeutics to alter the course of neurodegenerative and other disorders. Cortexyme is targeting a specific, undisclosed infectious pathogen tied to neurodegeneration in humans and animal models. Proprietary small molecules are currently in preclinical testing. For more information on Cortexyme, visit www.cortexyme.com.